Introduction
From an infectious disease perspective, the blood supply in developed countries is remarkably safe. Extant safeguards include exclusive collection from voluntary nonremunerated blood donors, risk-based donor selection, and the use of high-performance laboratory testing [often replete with parallel serological and nucleic acid testing (NAT)], in addition to robust quality assurance systems [1, 2] . Such is not the case for most low-income countries, where infectious risk remains an enduring challenge [3, 4] . Indeed, one study concluded that the risks of becoming infected with HIV, HBV and HCV from a blood transfusion in sub-Saharan Africa were 1, 4Á3 and 2Á5 infections per 1000 units, respectively [5] . While programs such as the U.S. President's Emergency Plan for AIDS and the Global Fund to Fight AIDS, Tuberculosis and Malaria have provided worldwide blood safety funding from 2000 to 2015, funding has declined since 2010 [6] . Infectious risk remains a multifaceted and systemic problem that spans lack of funding, limited infrastructure, a high prevalence of the major transfusiontransmitted infections (TTIs), suboptimal testing strategies and dependence on a high-risk donor pool comprising large numbers of first-time and replacement donors [3] .
The majority of testing for the major TTIs (e.g. HIV, HBV and HCV) in Africa is antibody based, thus neglecting the contribution of recent (window period) infection to transfusion risk. In contrast, the relatively high cost of molecular testing, which is better able to identify early infections, falls beyond the means of most African countries [7, 8] . Because the time from recognition of risk to implementation of a licensed assay can be lengthy, laboratory testing is also a suboptimal approach for the exclusion of emerging infections from the blood supply. In general, only under exceptional circumstances and with substantial political and financial commitment can development and implementation of testing begin to match the pace of an epidemic, as has occurred with implementation of NAT for West Nile virus (WNV) [9] and, most recently, Zika virus (ZIKV) in the United States (U.S.) [10] .
A new approach is needed to address TTI risk in lowresource settings. Pathogen reduction (PR) is an allencompassing term for a variety of methods (e.g. solvent detergent treatment or photochemical activation) that may be applied to blood following collection in a manner that confers broad protection against multiple infectious agents. These methods are also known by proprietary terms such as pathogen inactivation (PI, Cerus â ) or pathogen reduction technology (PRT, Terumo â ) [11] .
Many of these technologies are effective against different classes of pathogens (i.e. viruses, bacteria and parasites), offering the ability to interdict agents that are known to be transfusion-transmissible as well as emerging pathogens that pose uncertain risks to the blood supply. This is appealing, particularly in resource-limited settings where testing may be incomplete. Although developed to complement current testing, PR could ultimately prove to be an alternative to testing. Nonetheless, PR is still a nascent technology and there are formidable barriers to overcome. Here, we review extant PR technologies to evaluate their application to Africa. We recognize that many countries outside of Africa share similar constraints in which PR could offer potential solutions.
Materials and methods
A PubMed search was conducted of articles published between 2000 and 2016 using the following search terms either alone or in combination: 'Africa', 'sub-Saharan Africa', 'blood transfusion', 'blood donor', 'pathogen reduction', 'transfusion-transmitted infections', 'pathogen inactivation', and the individual technologies ('Mirasol', 'Intercept', 'Theraflex', etc.). This was extended to a general Google search of similar combinations of the same terms. References for the individual infectious agents were identified using the named pathogens ('malaria', 'Ebola', 'HIV', etc.) as search terms in combination with 'blood transfusion', 'transfusion-transmitted', and/or 'emerging diseases'. The search terms were developed to focus on the PR technologies available. Although our focus was on PR and TTIs in Africa, studies involving PR performed in other regions of the world, including Reunion Island, French Polynesia and Puerto Rico, were included in the search. We recognize that there are shared challenges among resource-poor and remote settings; however, the review has been focused on Africa specifically. The search was restricted to English language publications and publications that were previously translated to English. Additional content was obtained through review of the grey literature including the websites of companies that produce PR methods. We also reviewed articles that evaluated the development, implementation and outcomes of PR, those that pertain to TTIs and the safety of the blood supply in Africa and the prevalence of infectious diseases in Africa. The initial search produced 3396 articles, and a total of 93 publications met the search criteria and were included. 
Results

Photochemical inactivation
HIV (AIDS) 4Á46 -0Á39 (intracellular) 5Á93 -0Á20 (cell associated) >6Á1 1 Á4 (cell free) West Nile virus (WNV) 5Á19 -0Á50 >6 5 Á4 Hepatitis C virus (HCV) 5Á1 -0Á5 >4Á5
Hepatitis B virus (HBV) 2Á3 >5Á5
Hepatitis E virus (HEV), genotypes 3 and 4 >3 and >2, respectively Human T-lymphotropic virus type 1 (HTLV-1) 4Á7 Human T-lymphotropic virus type 2 (HTLV-2) 5Á1 Chikungunya (CHIKV) 1Á2, 2Á2 and 3Á5 log TCID50/ml at 50, 100 and 150% Mirasol energy dose, respectively 
Solvent/detergent and filtration methods
There are a variety of other PR approaches including pasteurization, solvent/detergent (S/D) treatment (Octaplas â ) and filtration [53] . Most are in use for acellular products, such as plasma and plasma derivatives (e.g. fibrinogen concentrates), as lipid membranes are destroyed during treatment but proteins can remain unaffected [54] . Solvent/detergent treatment has become widely used in Europe after it was first patented for application to coagulation factor concentrates [54] . During treatment, frozen plasma is rapidly thawed and filtered through a 1 lm filter. Large plasma pools collected from hundreds of donors are treated with a detergent for several hours. The agents are subsequently removed by a process of extraction using castor or soybean oil and hydrophobic chromatography, after which the plasma undergoes sterile filtration through a 0Á2 lm filter. The product is packaged into either frozen or lyophilized units. Stringent cleaning and sanitization of machinery is necessary between batches to prevent cross-contamination [53] .
Solvent/detergent treatment is very effective against a broad array of pathogens including enveloped viruses (e.g. HIV and HBV), bacteria, protozoa and intracellular viruses (e.g. CMV, EBV, HTLV I/II, CHIKV, and WNV) [55, 56] . Sterilization is further bolstered both by filtration and neutralizing antibodies from multiple donors in pooled plasma, who have been previously vaccinated or exposed to selected pathogens. Between 1991 and 2009, there was not a single reported case of transfusion-related transmission of HBV, HCV or HIV attributed to S/D plasma in Europe and South Africa, where approximately 10 million units were transfused [55] . Unfortunately, S/D is comparatively less effective against nonenveloped viruses, and transmission of HAV and parvovirus has still been reported [54] . Consequently, nucleic acid testing for these pathogens is routine for sourced plasma donors [57] . A further refinement step was incorporated in 2009 to reduce prion risk in the plasma manufacturing process, yet theoretical risk of prion exposure remains [55] . Studies have shown that there is no significant clinical difference in between S/D plasma and standard plasma. In fact, patients receiving S/D plasma have shown a lower incidence of adverse events such as transfusion-associated acute lung injury (TRALI) and allergic transfusion reactions [54, 55, [58] [59] [60] . Treatment and donor pooling also provide greater standardization of coagulation factors as compared to single-donor units of plasma [54, 55, 58, 59, 61] .
Chemical treatment
S-303 (Cerus Corporation, Concord, CA, USA)
S-303 (amustaline) is an alkylating agent that is used to treat RBCs. S-303 covalently modifies nucleic acids, inactivating pathogens through degradation to S-300. The first-generation S-303 compound was removed from the market after patients that received S-303-treated RBCs developed antibodies against neoantigens on the surface of treated RBCs [49] . Clinical trials are underway to evaluate a second-generation S-303 product. Glutathione is added as a quenching agent to minimize interaction of S-303 with extracellular proteins, thereby diminishing undesirable plasma protein degradation [62] . In a Phase I study of the second-generation product, RBC recovery at 24 h was similar between S-303-treated and untreated products; however, the life span of S-303-treated RBCs was reduced from 88 to 75 days [49].
Discussion
Pathogen reduction offers wide-ranging benefits, notably conferring protection against pathogens with established transfusion risk yet lack an effective or comprehensive screening strategy. With rare exception, blood donor infectious screening in Africa is focused on HIV, HBV, HCV and syphilis, all of which are widely endemic in Africa [3, [63] [64] [65] [66] . Importantly, testing is not universally available, particularly with respect to HCV, and has shown to be highly variable with respect to quality [67] [68] [69] .
In Africa, malaria and bacterial contamination constitute major, unaddressed transfusion-associated infection risks. Malaria is highly endemic and poses a complex challenge given the high prevalence (10Á2%) of infection in blood donors in endemic regions [70] , many of whom are asymptomatic at the time of donation. Laboratory testing for malaria is challenging. Microscopic examination of blood smears lacks sensitivity, requires technical expertise and is not amenable to high-throughput screening, while antibody testing is problematic given high rates of seropositivity due to frequent exposure and early development of semi-immunity in endemic areas [71] ; as such deferral for seroreactivity alone would be impractical. Immunochromatography-based rapid diagnostic tests (RDTs) -such as BinaxNOW -are attractive for use in low-resource areas give rapid turnaround and ease of use. However, their application is intended for use in clinical rather than donor screening. Donors are asymptomatic, reflecting low parasitemia, thus requiring a higher test sensitivity. Additional considerations include high rates of false positivity with certain formulations (i.e. histidinerich protein 2-based RDTs), and a requirement for blood smears to confirm negative test results [72, 73] . While molecular testing is highly sensitive and specific, the required infrastructure and technical expertise preclude widespread implementation [70] .
Bacterial contamination of blood products (notably platelets) is largely neglected in Africa. Inattention to sterile technique during blood collection and processing, hot and humid conditions, and inadequate cold chain management all increase the risk of bacterial contamination. Safeguards against bacterial contamination such as diversion pouches and blood culture, which are in routine use in high-income countries (HICs), are not widely available and/or applied in resource-constrained settings. Studies in Africa have shown bacterial contamination rates range from 2% to 17Á5%, compared to an estimated 1 of 3000 units in the United States [74, 75] .
Pathogen reduction could diminish these infectious risks; it would also contend with emerging and re-emerging infectious pathogens. Zika virus (ZIKV), named for the Ziika Forest in Uganda where it was first described, is merely one such example [76] . Similarly, there are sporadic outbreaks of dengue, Chikungunya (CHIKV), WNV, and yellow fever viruses in Africa. On occasion, outbreaks have had major, adverse effect on transfusion services [2, [77] [78] [79] [80] . The 2014 Ebola virus epidemic in West Africa was emblematic of the unpredictable nature and associated dangers of emerging infectious diseases. Ebola transmission via blood and body fluids is well established. No blood transfusion-transmitted cases of Ebola infections were reported, although this is ascribed to the severity of clinical presentation rendering donation highly unlikely when individuals are most contagious. In fact, plasma from convalescent individuals, containing high levels of Ebola neutralizing antibodies, was evaluated for use as adjunct treatment for infected patients [49, 81, 82] .
Despite these promising aspects, the use or even simply the evaluation of PR in Africa is still rare. Although the aforementioned examples suggest that rapid implementation of PR in a remote or under-resourced setting is feasible, these examples have been confined to crisis situations or highly controlled research studies. While important as proof of concept, implementation has drawn on substantial external support, which typically exceeds that which is routinely available to regional transfusion services. If widespread introduction of PR is to move forward in Africa, operational research is needed to assess how these technologies can be integrated, practically given the extant challenges of low-resource settings. There is a need for formal assessment of the feasibility of implementation and sustainability. This would include evaluation of training, reagents and other supplies, throughput, and efficacy against a range of local transfusion-transmissible pathogens. Although there are data to support comparable efficacy with standard (untreated) products, local evaluation is also important. The broader question is how this might be operationalized beyond the implementation phase.
Cost is frequently cited as a barrier to implementation of PR. Diminishing external funding has imposed significant challenges to African transfusion services. In some countries, the projected cost of photochemical treatment could exceed that of a locally collected unit; where even NAT falls beyond the means of most African countries, this cannot be ignored. Although PR has been implemented in low-resource settings in a matter of weeks in crisis situations, less urgent implementation may take months. Technical requirements such as reliable electricity also argue against PR implementation in low-resource countries. Nonetheless, cost-utility analyses are needed to evaluate approaches using PR as a stand-alone measure, as well as in combination with current and/or attenuated testing. This would serve to quantify the benefit of PR explicitly, thus guiding rational decision-making. Finally, innovation that bypasses dependence on electricity, high-complexity equipment and the associated need for skilled personnel, could afford access to blood transfusion in remote areas.
Pathogen reduction is a logical and innovative step towards comprehensive mitigation of transfusion-associated infectious risk. The benefits of PR are amplified in a low-resource, high-risk settings as is common in Africa.
Momentum for PR has been somewhat slow with its adoption still confined to sporadic use in HICs, due to high associated cost, regulatory and technical complexity inherent to implementation. Even so, other arguments against wider adoption in HICs do not necessarily apply to parts of Africa and other lowresource settings. Specifically, application of PR to resource-poor areas represents less a refinement of practice as is the case in HICs (i.e. where comprehensive testing and irradiation is typical); instead it could address critical areas of deficiency (e.g. mitigation of bacterial contamination, transfusion-transmitted malaria, GvHD). Indeed, the cost-effectiveness of PR is most favourable in those countries where infectious screening programs are least developed [86] . While it seems that there is a long road ahead, PR holds promise for prevention of TTIs in Africa. 
